JP7125144B2 - エクトヌクレオチダーゼ阻害剤およびその使用方法 - Google Patents

エクトヌクレオチダーゼ阻害剤およびその使用方法 Download PDF

Info

Publication number
JP7125144B2
JP7125144B2 JP2019513067A JP2019513067A JP7125144B2 JP 7125144 B2 JP7125144 B2 JP 7125144B2 JP 2019513067 A JP2019513067 A JP 2019513067A JP 2019513067 A JP2019513067 A JP 2019513067A JP 7125144 B2 JP7125144 B2 JP 7125144B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
fluoro
halo
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530669A (ja
JP2019530669A5 (enExample
Inventor
リジン チェン，
ジム リー，
エリック ビー． ジョグレン，
ローランド ジョセフ ビレドー，
Original Assignee
キャリセラ バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャリセラ バイオサイエンシーズ， インコーポレイテッド filed Critical キャリセラ バイオサイエンシーズ， インコーポレイテッド
Publication of JP2019530669A publication Critical patent/JP2019530669A/ja
Publication of JP2019530669A5 publication Critical patent/JP2019530669A5/ja
Application granted granted Critical
Publication of JP7125144B2 publication Critical patent/JP7125144B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019513067A 2016-09-09 2017-09-08 エクトヌクレオチダーゼ阻害剤およびその使用方法 Active JP7125144B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662385730P 2016-09-09 2016-09-09
US62/385,730 2016-09-09
PCT/US2017/050659 WO2018049145A1 (en) 2016-09-09 2017-09-08 Ectonucleotidase inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019530669A JP2019530669A (ja) 2019-10-24
JP2019530669A5 JP2019530669A5 (enExample) 2020-10-15
JP7125144B2 true JP7125144B2 (ja) 2022-08-24

Family

ID=61559594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513067A Active JP7125144B2 (ja) 2016-09-09 2017-09-08 エクトヌクレオチダーゼ阻害剤およびその使用方法

Country Status (6)

Country Link
US (2) US10472364B2 (enExample)
EP (1) EP3510040A4 (enExample)
JP (1) JP7125144B2 (enExample)
CN (1) CN110234656B (enExample)
TW (1) TWI767937B (enExample)
WO (1) WO2018049145A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7125144B2 (ja) * 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
CA3047988A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US12226479B2 (en) * 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
IL304348B2 (en) * 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
CN112888696B (zh) 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法
EP3843742A4 (en) 2018-08-28 2022-04-20 Jiangsu Hengrui Medicine Co., Ltd. CD73 INHIBITORS AND THEIR THERAPEUTIC USES
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
US10881681B2 (en) 2018-09-11 2021-01-05 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
AU2019360210B2 (en) * 2018-10-17 2025-07-10 Xibin Liao 6-Mercaptopurine nucleoside analogues
WO2020190073A1 (ko) * 2019-03-20 2020-09-24 한국화학연구원 신규한 아졸로피리미딘 헤테로고리 화합물을 유효 성분으로 함유하는 약제학적 조성물
WO2020205538A1 (en) * 2019-03-29 2020-10-08 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
CA3143496A1 (en) * 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CA3159248C (en) * 2019-10-30 2024-05-28 Oric Pharmaceuticals, Inc. Cd73 inhibitors
AU2021341258A1 (en) * 2020-09-08 2023-04-13 Betta Pharmaceuticals Co., Ltd. CD73 inhibitor and application thereof in medicine
CN114099698B (zh) * 2021-11-26 2024-02-09 山东大学齐鲁医院 一种pH敏感脂质体及其制备方法与应用
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN117430651A (zh) * 2022-07-21 2024-01-23 武汉精准智药科技有限公司 单磷酸核苷类化合物及其制备方法
CN115611954A (zh) * 2022-12-19 2023-01-17 天津奥瑞芙生物医药有限公司 一种5′-o-(4,4′-二甲氧基三苯甲基)-核苷的制备方法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2017024310A1 (en) 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
JP2020504735A (ja) 2016-12-22 2020-02-13 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
CA2085994A1 (en) 1991-04-24 1992-10-25 Shinji Sakata 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
WO1994010128A1 (en) 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004096233A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US8512717B2 (en) 2003-08-07 2013-08-20 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
US8603998B2 (en) 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
CN103209970B (zh) 2010-07-08 2016-08-24 生命科技公司 原位化学发光底物和测定
WO2012151142A2 (en) 2011-05-03 2012-11-08 Life Technologies Corporation Flash and glow 1,2-dioxetanes
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017079195A1 (en) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
CA3151595A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
JP7125144B2 (ja) * 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2017024310A1 (en) 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
JP2020504735A (ja) 2016-12-22 2020-02-13 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database REGISTRY，2011年，RN 1260067-82-0, 1260067-78-4, 1259875-56-3; Retrieved fromSTN international [online] ;retrieved on 1 September 2021
DEBARGE,S. et al，Design and Synthesis of α-Carboxy Phosphono-Nucleosides，Journal of OrganicChemistry，2011年，Vol.76, No.1，p.105-126
HLADEZUK,I. et al，Development of O-H insertion for the attachment of phosphonates to nucleosides;synthesis of α-carboxy phosphononucleosides，Tetrahedron，2012年，Vol.68, No.7，p.1894-1909

Also Published As

Publication number Publication date
EP3510040A1 (en) 2019-07-17
US11208414B2 (en) 2021-12-28
JP2019530669A (ja) 2019-10-24
CN110234656A (zh) 2019-09-13
US20200087310A1 (en) 2020-03-19
EP3510040A4 (en) 2020-06-03
TW201811775A (zh) 2018-04-01
WO2018049145A1 (en) 2018-03-15
TWI767937B (zh) 2022-06-21
US20180072742A1 (en) 2018-03-15
US10472364B2 (en) 2019-11-12
CN110234656B (zh) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7125144B2 (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
JP7138351B2 (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
US12421273B2 (en) Ectonucleotidase inhibitors and methods of use thereof
JP2022537358A (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220603

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220613

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220804

R150 Certificate of patent or registration of utility model

Ref document number: 7125144

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250